Navigation Links
Researchers validate preclinical effectiveness of TB drug target
Date:11/29/2011

Menlo Park, Calif. -- In research at SRI International, scientists evaluating new drug targets against tuberculosis (TB) recently validated the preclinical effectiveness of a target that could rapidly eliminate infections and potentially shorten treatment time. The new drug target is a protein called DNA gyrase B, found in bacteria that cause TB infections.

DNA gyrase is an enzyme consisting of two subunits: gyrase A and gyrase B. Although gyrase A is often the target of antibiotics, such as ciprofloxacin, there currently is no antibiotic on the market that targets gyrase B. In laboratory experiments, SRI researchers found that by targeting gyrase B, TB bacteria are killed whether they are replicating or dormant. Further studies will be conducted toward the development of a TB drug against gyrase B.

"One of the greatest needs in infectious disease treatment is a drug that allows a shorter length of treatment," said Peter Madrid, Ph.D., program director in the Center for Infectious Disease and Biodefense Research, SRI Biosciences Division. "Though our program is still in the preclinical phase of research, with a number of years of required testing ahead, our goal is to develop a drug that will improve the treatment process for TB patients."

TB patients currently undergo treatment for six months and take a combination of at least four different drugs. There are often challenges to treatment effectiveness because of the long treatment time, including low patient treatment compliance and high rates of drug resistance. Tuberculosis that is resistant to multiple drugs takes even longer to treat, usually 18 to 24 months.


'/>"/>
Contact: Dina Basin
dina.basin@sri.com
650-859-3845
SRI International
Source:Eurekalert

Page: 1

Related medicine news :

1. Researchers surprised to find fatty liver disease poses no excess risk for death
2. Moffitt Cancer Center researchers find men less willing to be screened for cancer
3. MU researchers find synthetic RNA lessens severity of fatal disease
4. Researchers search for culprit behind dry eyes, mouths and more
5. MU researchers develop tool that saves time, eliminates mistakes in diabetes care
6. Researchers discover new way to form extracellular vesicles
7. Researchers discover Achilles heel in lethal form of prostate cancer
8. Jackson Laboratory researchers uncover steps in synapse building, pruning
9. UCLA stem cell researchers uncover mechanism that regulates human pluripotent stem cell metabolism
10. Ben-Gurion University of the Negev researchers achieve male fertility breakthrough
11. Canadian researchers find potential new leukemia treatment with old antibiotic drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... November 22, 2014 "My friend went ... caused by the machine," said an inventor from Cambria ... to go back a second time because the first ... , She developed the patent-pending MAMO EASY to offer ... The design saves the patient from the pain normally ...
(Date:11/22/2014)... Lipitor lawsuits ( http://www.lipitorlawsuitcenter.com/ ) that ... developed Type 2 diabetes due to its use continue ... underway in U.S. District Court, District of South Carolina, ... litigation will convene its next Status Conference on December ... Counsel for Plaintiffs and Defendants to meet and confer, ...
(Date:11/22/2014)... Eugene, OR (PRWEB) November 22, 2014 The ... addition of Roy Baroff to its team of ... lawyer, mediator, soccer player, coach, and referee. He has over ... North Carolina and beyond. , “I'm very excited to connect ... experience and sports related interests to a program with a ...
(Date:11/22/2014)... Columbus, OH (PRWEB) November 22, 2014 ... trials for AndroGel side-effects lawsuits have been scheduled ... District Court, Northern District of Illinois. U.S. District Judge ... litigation, issued a Case Management Order (CMO) on November ... as deadlines for attorneys to submit documents and other ...
(Date:11/22/2014)... Steven Reinberg HealthDay Reporter ... outcomes are better when patients are treated in an ambulance ... drugs, German researchers report. The sooner patients get the ... the outcome after a stroke, the researchers noted. For the ... first hour after stroke symptoms start, the researchers said. ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3Health News:SCI Announces New Team Member Roy Baroff 2Health News:SCI Announces New Team Member Roy Baroff 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 2Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 4Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 2Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 3
... shows long-term weight control is achievable, Abstract 34, ... weight and want to keep it off might benefit ... Heart,Association,s Conference on Nutrition, Physical Activity and Metabolism., ... in the,Journal of the American Medical Association., In ...
... rates in follicular non-Hodgkin lymphoma , , THURSDAY, ... chemotherapy is safe and effective for patients ... an Italian study. , It found that ... ibritumombab tiuxetan, following chemotherapy with fludarabine and ...
... 13 Weight Watchers,International, Inc. (NYSE: WTW ) ... cash dividend of $0.175 per share, which corresponds,to an ... dividend will,be payable on April 11, 2008 to shareholders ... 2008., About Weight Watchers International, Inc., Weight ...
... on display, MINNEAPOLIS, March 13 This month, ... the free, professional,counseling from QUITPLAN(R) Services to successfully quit ... Capitol. The exhibits are on display,from Sunday, March 16 ... State,Capitol near the Rotunda., "The Capitol display is ...
... March 13 Setting the foundation for,continuing the ... Clinical Services (DCS) announced today that it doubled ... of outsourced,wound care, DCS will now have 20 ... regional senior vice presidents. With approximately 300,hospital partners ...
... Md., March 13 HHS, Agency for,Healthcare Research ... new health,information technology contracts that will focus on ... using clinical,decision support. Clinical decision support helps health ... and Women,s Hospital in Boston and Yale University ...
Cached Medicine News:Health News:American Heart Association Meeting Report 2Health News:American Heart Association Meeting Report 3Health News:American Heart Association Meeting Report 4Health News:American Heart Association Meeting Report 5Health News:American Heart Association Meeting Report 6Health News:American Heart Association Meeting Report 7Health News:American Heart Association Meeting Report 8Health News:American Heart Association Meeting Report 9Health News:American Heart Association Meeting Report 10Health News:American Heart Association Meeting Report 11Health News:American Heart Association Meeting Report 12Health News:American Heart Association Meeting Report 13Health News:Radioimmunotherapy After Chemo Safe for Common Lymphoma 2Health News:Weight Watchers Declares Quarterly Dividend 2Health News:ClearWay Minnesota(SM) Celebrates QUITPLAN(R) Services at the Capitol 2Health News:ClearWay Minnesota(SM) Celebrates QUITPLAN(R) Services at the Capitol 3Health News:Diversified Clinical Services Doubles Field Management 2Health News:AHRQ Awards $5 Million to Help Integrate Clinical Decision Support Technologies Into Health Care Delivery 2
(Date:11/22/2014)... 21, 2014 Many power shifts are ... influence of patients in the biopharmaceutical market is ... more than ever, understanding how to effectively acquire, ... is essential. According to recent ... companies spent about two-thirds of their patient-focused dollars ...
(Date:11/21/2014)... 2014 In September 2014, the staff at ... a new product development plan that started with the ... lab coat , aptly named "Vera G.," after ... the world. The new women,s designer lab coat is ... sleek envelope collar, vertical princess and high waist seaming, ...
(Date:11/21/2014)... 21, 2014  PTC Therapeutics, Inc. (NASDAQ: PTCT ... Technology Award for Vision, Innovation, and Leadership has been awarded ... This award recognizes an individual who has had a significant ... for several decades. "I am honored ... Stuart Peltz , Ph.D., CEO of PTC Therapeutics, Inc. "When ...
Breaking Medicine Technology:New Report Details Importance of Adopting a "Patient Journey" Framework in Marketing 2Medelita Introduces Medical Industry's First Limited Edition Women's Designer Lab Coat 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 3
... 31, 2011 Polaris Group (Polaris) today announced that ... the company,s Special Protocol Assessment (SPA) for a Phase ... in patients with advanced hepatocellular carcinoma (HCC). The randomized, ... have failed prior systemic chemotherapy. The primary endpoint of ...
... 2011 Amarin Corporation plc (Nasdaq: AMRN ... cardiovascular disease, today announced that Executive Chairman and Chief ... EDT on April, 6, 2011 at the 10th Annual ... President, John Thero, will be available at the conference ...
Cached Medicine Technology:FDA Approves Special Protocol Assessment for Phase 3 Trial of Polaris Group's Cancer Therapeutic, ADI-PEG 20, in the Treatment of Hepatocellular Carcinoma 2FDA Approves Special Protocol Assessment for Phase 3 Trial of Polaris Group's Cancer Therapeutic, ADI-PEG 20, in the Treatment of Hepatocellular Carcinoma 3Amarin to Present at the 10th Annual Needham Healthcare Conference 2
... The Ulti-Mist™ HME product line has ... from pediatrics to adults and from intubated ... offer superior humidification for both anesthesia and ... and HME/Filters provide maximum protection for patients ...
The Pall High Performance HME is a high efficiency heat and moisture exchanger, indicated to protect patients against the potential risks of ventilation with dry and cold gases....
Passive heat and moisture exchangers for respiratory applications....
Passive heat and moisture exchangers for respiratory applications....
Medicine Products: